A United Kingdom supplier, with 3 awarded contracts, totalling £856.1m, most recently 3 weeks ago.
NHS is establishing a branded medicines framework agreement across English regions, with two separate lots for different geographical areas and contract durations starting September 2026.
Opportunity to supply Ustekinumab, an immunosuppressant biopharmaceutical medication for various therapeutic applications.
NHS is seeking suppliers for branded medicines across England in two regional lots, with framework agreements commencing September 2026.
Procurement for the supply of Transitional Drugs 7 from qualified pharmaceutical vendors.
